Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine

Qing Zhang¹,², Xun Han¹, Hangfei Wu¹, Mingjie Zhang¹, Guanqun Hu¹, Zhao Dong¹, and Shengyuan Yu¹

Abstract
Migraine is the seventh most disabling disorder globally, with prevalence of 11.7% worldwide. One of the prevailing mechanisms is the activation of the trigeminovascular system, and calcitonin gene-related peptide (CGRP) is an important therapeutic target for migraine in this system. Recent studies suggested an emerging role of pituitary adenylate cyclase-activating peptide (PACAP) in migraine. However, the relation between CGRP and PACAP and the role of PACAP in migraine remain undefined. In this study, we established a novel repetitive (one, three, and seven days) electrical stimulation model by stimulating dura mater in conscious rats. Then, we determined expression patterns in the trigeminal ganglion and the trigeminal nucleus caudalis of the trigeminovascular system. Electrical stimulation decreased facial mechanical thresholds, and the order of sensitivity was as follows: vibrissal pad > inner canthus > outer canthus (P < 0.001). The electrical stimulation group exhibited head-turning and head-flicks (P < 0.05) nociceptive behaviors. Importantly, electrical stimulation increased the expressions of CGRP, PACAP, and the PACAP-preferring type 1 (PAC1) receptor in both trigeminal ganglion and the trigeminal nucleus caudalis (P < 0.05). The expressions of two vasoactive intestinal peptide (VIP)-shared type 2 (VPAC1 and VPAC2) receptors were increased in the trigeminal ganglion, whereas in the trigeminal nucleus caudalis, their increases were peaked on Day 3 and then decreased by Day 7. PACAP was colocalized with NEUronal Nuclei (NeuN), PAC1, and CGRP in both trigeminal ganglion and the trigeminal nucleus caudalis. Our results demonstrate that the repetitive electrical stimulation model can simulate the allodynia during the migraine chronification, and PACAP plays a role in the pathogenesis of migraine potentially via PAC1 receptor.

Keywords
Migraine, electrical stimulation, calcitonin gene-related peptide, pituitary adenylate cyclase-activating peptide, PAC1 receptor

Date Received: 5 May 2018; revised: 22 July 2018; accepted: 7 August 2018

Introduction
Migraine is a severe brain disorder, listed as the seventh most disabling disorder globally by the World Health Organization,¹ with prevalence of 11.7% worldwide² and 9.3% in China.³ One of the prevailing mechanisms of migraine is the activation of the trigeminovascular system, which results in the pain feeling associated with multiple head regions. Nociceptive nerve fibers from the peripheral terminals of the trigeminal ganglion (TG) innervate intra- and extracranial vasculature and...
mенингес, приложив механическую стимуляцию, химическую стимуляцию, или электрическую стимуляцию (ES) к этим структурам, особенно к периферии. Эта ситуация может быть усугублена хроническим ишемическим напряжением сосудов. Применение вышеуказанных методов может привести к развитию мигреней и расширению краниоциркуляторного синуса.

**Materials and methods**

**Animals**

Согласно общепринятой концепции, мигрень на 30% более распространена у женщин, и, что еще более удивительно, женщины выставляют более высокий процент (около 10%) женских пациентов с мигренями. Только мужские животные использовались в этом исследовании. Сульфат Спрейд-Дэвиля был использован в общепринятом температурно-контролируемом (22 ± 2°C) и свето-контролируемом (12 ч темнота/свет) режиме. Животные использовались для экспериментального исследования и минимизации страданий. Это было одобрено Комитетом по экспериментальному использованию животных (University of California, Davis, CA, USA). Стимулирователь имплантировался в соответствии с вышеуказанными исследованиями.

**Experimental design**

Раты были случайно разбазаренные на четыре группы (n = 6 в каждой группе): Грппа (Шам), ES для одной группи (ES-1D), ES для трех групп (ES-3D) и ES для семи групп (ES-7D). Раты были размещены в домашней клетке для трех дней перед операцией, при которой был применен базальный механизм стимуляции (МТ) для определения чувствительности в областях (наружный глаз, внутренний глаз, и усиковая область) с помощью Frey monofilaments (North Coast Medical Co., Ltd., USA). Стимулирователь имплантировался в соответствии с вышеуказанными исследованиями.
ensure that MTs were back to baseline. The experimental apparatus and detailed stimulation procedures were applied as previously described. Rats in the ES-1D, ES-3D, and ES-7D groups received an ES (10 min, 20 Hz, 250 μs pulse duration, and 3–5 mA intensity) once daily for one day, consecutive three days, and seven days, respectively. Rats in the Sham group (Sham) were only connected to the stimulator without stimulation 10 min daily for seven days to control the possible influences of surgical and experimental procedures. Behaviors during the stimulating period (10 min) were recorded and analyzed by two researchers who were blind to the experimental design. Before daily stimulus, baselines of facial MTs on each day were determined using von Frey monofilaments. Afterward, facial MTs were determined at 0 min, 30 min, 60 min, and 90 min after stimulus.

**Facial MT**

Six patches of facial skin were tested clockwise (left vibrissal pad, left inner canthus, left outer canthus, right outer canthus, right inner canthus, and then right vibrissal pad) with von Frey filaments of force values determined in preexperiments (26, 15, 10, 8, 6, 4, 2, and 1 g, rats that did not respond to 26 g were assigned as 26 g) using an “up-down” paradigm. Von Frey filaments were applied perpendicularly to the tested area for 3 to 6 s until a positive response were observed: asymmetrical face grooming, withdraw, escape, or attack response. The force value at which two positive responses were noted in three trials was recorded as the MT. Average integrated value of bilateral areas was accepted as the final result for each animal.

**Tissue preparation**

Rats in different groups were humanely sacrificed at 90 min after the final stimulus. The TNC and bilateral TGs were carefully isolated and embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, CA, USA). Then, the base mold containing embedded tissue was submerged into liquid nitrogen for 10 to 20 s till the entire tissue block being frozen completely. Frozen tissue blocks were kept in −20°C for 24 h prior to sectioning. Frozen tissue blocks were cut into 20-μm-thick serial sections using a freezing microtome (CM1850; Leica, Wetzlar, Germany), followed by fixation in precooled acetone (−20°C) for 20 min. Hematoxylin and eosin (H&E) staining and Nissl staining were carried out following standard protocols.

To control for the uneven distribution of TG neurons, we prepared 12 sets of sequential slides per animal (6 × 20-μm-thick sections/slide) using an “S-shape” strategy, which means that Slide 1 had the 1st, 13th, 25th, 37th, 49th, and 61st sequential sections of the TG. In addition, slides of the same number (e.g. Slide 1) from different animals were used for the staining of one specified marker (e.g. immunohistochemistry (IHC) for PACAP). This strategy would hopefully lessen the disturbance of uneven distribution of the TG neurons and provide an average estimation of the whole TG neurons.

**Immunohistochemistry**

Frozen sections underwent heat-induced epitope retrieval (submerged in 90°C water bath for 2 min. Retrieval solution: 0.3% sodium citrate, 0.04% citric acid, and pH 6.0), endogenous enzyme interference (incubated in 3% H2O2 solution), and endogenous biotin interference (incubated in IHC Biotin Block Kit, BLK-0002; Maixin Biological Technology, Ltd., Fujian, China). Afterward, sections were blocked with 10% goat serum (ZLI-9005, ZSGB-BIO, China) at 37°C for 1 h and were incubated at 4°C overnight with respective diluted primary antibodies (Table 1). On the second day, sections were incubated with secondary antibody for 1 h at room temperature (HRP-Polymer anti-Mouse/Rabbit IHC Kit, KIT-5030; Maixin Biological Technology, Ltd., China), followed by incubation of 3,3′-diaminobenzidine (ZLI-9018, ZSGB-BIO, China) for 1 to 5 min at room temperature.

**Immunofluorescence**

Frozen sections underwent endogenous enzyme interference and endogenous biotin interference and blocking as described earlier. Thereafter, sections were incubated at 4°C overnight with combinations of diluted primary antibodies.

### Table 1. Primary Antibodies Used for Immunohistochemistry.

| Name  | Host   | Dilutions | Catalog  | Source         | Citations          |
|-------|--------|-----------|----------|----------------|--------------------|
| PACAP | Mouse  | 1:80      | sc-25439 | Santa Cruz, USA| Castorina et al. |   |
| CGRP  | Mouse  | 1:50      | ab81887  | Abcam, UK      | Eftekhari et al.   |   |
| PAC1  | Mouse  | 1:400     | ab54980  | Abcam, UK      | Kanasaki et al.    |   |
| VPAC1 | Rabbit | 1:50      | sc-30019 | Santa Cruz, USA| Csaki et al.       |   |
| VPAC2 | Rabbit | 1:50      | sc-30020 | Santa Cruz, USA| Csaki et al.       |   |

CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating peptide; PAC1: ■; VPAC1: ■; VPAC2: ■.
Figure 1 shows the changes in daily MTs before and after stimulation (within 90 min), which represented the outer canthus, inner canthus, and vibrissal pad before and after daily stimulation (within 90 min), which represented the chronic and acute effects of ES, respectively, and the Sham group. The MTs of both outer canthus (a) and inner canthus (b) in the ES group decreased as the days of stimulation increased (P < 0.05), and there were significant differences between the ES group and the Sham group (a. **P < 0.01; b. ***P < 0.001). The most prominent time-dependent decrease was seen in vibrissal pad (c, P < 0.001). MTs of vibrissal pad in the ES group were significantly lower than those of the Sham group (***P < 0.001), beginning from Day 3 (##P < 0.01) and further lowering during Days 5 to 7 (###P < 0.001). (d) Collectively, there were significant differences in MTs among outer canthus, inner canthus, and vibrissal pad in the ES group (**P < 0.001), with MTs of vibrissal pad apparently lower than that of outer canthus beginning from Day 3 (Day 3: *P < 0.01; Day 4: *P < 0.01; Days 5 to 7: ***P < 0.001).

To investigate whether acute effects of stimulation contributed to the gradual decrease in MTs in the ES group, we measured MTs of outer canthus, inner canthus, and vibrissal pad within 90 min after daily stimulation (Figure 2). Similarly, there were significant differences among three areas in the ES group starting from Day 2 (*P < 0.05) to Day 7 (Days 3 to 7: ***P < 0.001). However, no significant relationships between MTs and poststimulus time were found during the experimental period, except on Day 4 (P < 0.01) and Day 7 (P < 0.05). In other words, ES was not able to effectively lower MTs within 90 min after stimulation. Collectively, these results suggest that the repetitive ES can decrease the facial MTs potentially via chronic effects.

**Nociceptive behaviors were induced in the repetitive ES model**

To evaluate whether the repetitive ES model can simulate the frequent onset of acute migraine, we investigated four kinds of nociceptive behaviors in conscious rats as described in our previous works33,43: facial grooming, body grooming, head-flicks, and head-turning. As shown in Figure 3(a), facial grooming time of the ES group was significantly higher than that of the Sham group on Day 1 (*P < 0.05), while no apparent differences were observed thereafter. In preexperiments, we noticed that body grooming was always observed alternatively with facial grooming. Given that facial grooming has been accepted as a kind of nociceptive behavior.

### Table 2. Primary Antibodies Used for Immunofluorescence.

| Name   | Host   | Dilutions | Catalog   | Source          | Citations        |
|--------|--------|-----------|-----------|-----------------|------------------|
| PACAP  | Rabbit | 1:50      | ab174982  | Abcam, UK       | Kortesi et al.41  |
| CGRP   | Mouse  | 1:50      | ab81887   | Abcam, UK       | Eftekhari et al.38|
| PAC1   | Mouse  | 1:100     | ab54980   | Abcam, UK       | Kanasaki et al.39 |
| NeuN   | Mouse  | 1:3000    | MAB337    | Merck Millipore, Germany | Borsani et al.42 |

CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating peptide; PAC1: |

antibodies: anti-PACAP and anti-NEUronal Nuclei (NeuN), anti-PACAP and anti-PAC1, and anti-PACAP and anti-CGRP (Table 2). On the second day, sections were incubated with the combination of rabbit immunoglobulin (IgG) secondary antibody (1:500, A-11034; Thermo Fisher) and mouse IgG secondary antibody (1:1000, A-21424, Thermo Fisher). For the analysis of IHC and immunofluorescence (IF) results, six results were obtained (one image/section, six sections/animal) at 20× magnification of the TG and six images (bilateral images/section, three sections/animal) at 50× magnification of the TNC were randomly selected using a microscope (DP73; Olympus, Tokyo, Japan). Average integrated density of six images was accepted as the final result for each animal.

**Statistical analysis**

SPSS 19.0 software was applied for the statistical analysis, and Graphpad Prism 6 software was used to generate the graphs. Shapiro–Wilk test was first conducted to test the normality followed by Levene’s test for the homogeneity. Normally distributed data were analyzed using analysis of variance (ANOVA) and Fisher’s least significant difference test (with regular variance) or Dunnett’s T3 test (with irregular variance) for comparisons between the groups. For abnormally distributed data, Kruskal–Wallis test was used to determine differences among the groups. Repeated measures ANOVA was used to compare differences in MTs between groups. The results were accepted from “sphericity assumed” option if the assumption of Mauchly’s test was met or from “lower-bound” option if the assumption was violated. A value of P < 0.05 was considered significant.

**Results**

**Repetitive ES of the dura mater decreased facial MTs via chronic effect**

To investigate whether repetitive ES of the dura mater surrounding the superior sagittal sinus can simulate the allodynia of migraine, we first determined the MTs of outer canthus, inner canthus, and vibrissal pad before and after stimulation (within 90 min), which represented the chronic and acute effects of ES, respectively. Figure 1 shows the changes in daily MTs before stimulation. The MTs of both outer canthus (a) and inner canthus (b) in the ES group decreased as the days of stimulation increased (P < 0.05), and there were significant differences between the ES group and the Sham group (a. **P < 0.01; b. ***P < 0.001). The most prominent time-dependent decrease was seen in vibrissal pad (c, P < 0.001). MTs of vibrissal pad in the ES group were significantly lower than those of the Sham group (***P < 0.001), beginning from Day 3 (##P < 0.01) and further lowering during Days 5 to 7 (###P < 0.001). (d) Collectively, there were significant differences in MTs among outer canthus, inner canthus, and vibrissal pad in the ES group (**P < 0.001), with MTs of vibrissal pad apparently lower than that of outer canthus beginning from Day 3 (Day 3: *P < 0.01; Day 4: *P < 0.01; Days 5 to 7: ***P < 0.001).

To investigate whether acute effects of stimulation contributed to the gradual decrease in MTs in the ES group, we measured MTs of outer canthus, inner canthus, and vibrissal pad within 90 min after daily stimulation (Figure 2). Similarly, there were significant differences among three areas in the ES group starting from Day 2 (*P < 0.05) to Day 7 (Days 3 to 7: ***P < 0.001). However, no significant relationships between MTs and poststimulus time were found during the experimental period, except on Day 4 (P < 0.01) and Day 7 (P < 0.05). In other words, ES was not able to effectively lower MTs within 90 min after stimulation. Collectively, these results suggest that the repetitive ES can decrease the facial MTs potentially via chronic effects.

**Nociceptive behaviors were induced in the repetitive ES model**

To evaluate whether the repetitive ES model can simulate the frequent onset of acute migraine, we investigated four kinds of nociceptive behaviors in conscious rats as described in our previous works33,43: facial grooming, body grooming, head-flicks, and head-turning. As shown in Figure 3(a), facial grooming time of the ES group was significantly higher than that of the Sham group on Day 1 (*P < 0.05), while no apparent differences were observed thereafter. In preexperiments, we noticed that body grooming was always observed alternatively with facial grooming. Given that facial grooming has been accepted as a kind of nociceptive behavior.
in the ES rat model of migraine, we investigated whether body grooming behavior could also be affected in the repetitive ES model. As expected, the trends of body grooming time were very similar to those of facial grooming time. However, no significant differences between groups were found during the experimental period (Figure 3(b)). Head-turning, characterized by turning head to one side of the body and keeping this position for 1 to 3 s, was only observed in the ES group (*P < 0.05, Figure 3(c)). Head-flicks is characterized by nonrhythmic quick shaking of head, and it often occurs before or after facial and body grooming. The overall numbers of the head-flicks in the ES group were not less than those of the Sham group, with significantly greater numbers on Days 3 and 6 (*P < 0.05; **P < 0.01; ***P < 0.001, Figure 3(d)). We also analyzed exploration time during stimulation but did not find apparent differences between groups in rest and exploration behaviors (Figure 3(e) and (f)).

Dynamic expressions of CGRP, PACAP, PAC1, VPAC1, and VPAC2 receptors in the TG and the TNC during repetitive ES

Based on the repetitive ES model, we investigated the number of cells that express CGRP, PACAP and its three receptors, namely, PAC1, VPAC1, VPAC2, in the TG and the TNC via IHC. We proposed to investigate the role of PACAP in migraine from two perspectives: (1) compare the expression patterns of CGRP and PACAP and further evaluate the model by dynamic expressions of CGRP and (2) investigate the expression patterns of PACAP receptors. Central afferent projections from the TG terminate in the spinal trigeminal nucleus caudalis (Sp5C) of the TNC. Recent study in rats also showed that descending cortical projections innervated by the ophthalmic (V1) branch of the trigeminal nerve, originating from contralateral insular and primary somatosensory (S1) cortices, terminate, respectively, in laminae I to II and III to V of the Sp5C.

Therefore, the present study analyzed expression patterns of CGRP, PACAP, and its receptors in lamina III to V of the Sp5C (Figures 4 and 5).

The number of cells expressing CGRP in both TG and TNC increased steadily as the stimuli repeated (Figure 6(a) and (b)): the number of positive cells of the ES group on Day 3 (***P < 0.01) and Day 7 (TG: ***P < 0.001; TNC: **P < 0.01) was significantly higher than that of the Sham group. Similar trends were seen in the expression patterns of PACAP (Figure 6(c) and (d)). PACAP+ cells in the TG built up as times of stimuli increased,
Figure 2. Daily stimulation did not significantly alter facial MTs within 90 min. Data are represented by mean ± standard deviation, n = 6 for each group. (a) to (g) MTs of outer canthus, inner canthus, and vibrissal pad during 90 min after stimulation from Day 1 to Day 7. No significant relationships between time and MTs were found during the experimental period except on Day 4 (P < 0.01) and Day 7 (P < 0.05). There were significant differences among three areas since Day 2: *P < 0.05; ***P < 0.001.

ES: electrical stimulation.
with ES on Day 1, Day 3, and Day 7 significantly higher than the Sham group (***P < 0.001). Similarly, PACAP+ cells in the TNC were also elevated by the increasing stimuli: Day 3 (*P < 0.05) and Day 7 (**P < 0.01) were significantly higher than the Sham group.

Correspondingly, PAC1 receptor was also increased during the experimental period in both TG and TNC (Figure 6(e) and (f)). PAC1 was increased slowly, with levels on Day 1 being similar to the Sham group in both TG and TNC. Nevertheless, numbers of PAC1+ cells in...
both areas were higher on Day 3 (TG: *P < 0.05) and Day 7 (TG: *P < 0.05) compared with the Sham group. Interestingly, VPAC1 receptor and VPAC2 receptor exhibited more complex expression patterns, especially in the TNC. There were overt increases in VPAC1 expressing cells on Day 3 (*P < 0.05) and Day 7 (**P < 0.01) compared with the Sham group in the TG (Figure 6(g)). In the TNC, however, it went up during

**Figure 4.** Coordinates and structures of the TG and the TNC. (a) The stereotaxic coordinates of Sp5C in rat brain (adapted from Paxinos and Watson's work). The H&E (b) and Nissl (c) staining of the TNC-Sp5C. The present study analyzed expression patterns of CGRP, PACAP, and its receptors in lamina III to V of the Sp5C. The H&E (d) and Nissl (e) staining of the TG. TG: trigeminal ganglion; TNC: trigeminal nucleus caudalis; H&E: Hematoxylin and eosin; Sp5C: spinal trigeminal nucleus caudalis.

**Figure 5.** IHC staining of CGRP, PACAP, PAC1, VPAC1, and VPAC2 in the TG and the TNC. Images shown are randomly selected from the TG at 20x magnification and from the TNC at 50x magnification. PACAP-expressing fibers were found at lamina III to V of the Sp5C. CGRP-expressing fibers were mostly located at lamina I to II of the Sp5C (data not shown). TG: trigeminal ganglion; TNC: trigeminal nucleus caudalis; CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating peptide; PAC1: ■; VPAC1: ■; VPAC2: ■.
Figure 6. Dynamic expressions of CGRP, PACAP, PAC1, VPAC1, and VPAC2 receptors in the TG and the TNC during repetitive ES. Y-axis shows the average number of positive cells (six images per animal, six animals per group) at 20× magnification of the TG and at 50× magnification of the TNC as specified in "Materials and Methods" section. Data are represented by mean ± standard deviation. (a and b) The numbers of CGRP+ cells were increased in both TG and TNC during repetitive ES. (c and d) PACAP showed a similar pattern as CGRP; increased in both TG and TNC. (e and f) PAC1 receptor was increased from Day 3 to Day 7 in both TG and TNC. (g and h) VPAC1 receptor was increased from Day 3 to Day 7 in the TG, while in the TNC, it also peaked on Day 3 and then decreased by Day 7. (i and j) VPAC2 receptor reached a steady level from Day 1 to Day 7 in the TG, while in the TNC, it also peaked on Day 3 and then decreased by Day 7. Compared with the Sham group: *P < 0.05; **P < 0.01; ***P < 0.001.

TG: trigeminal ganglion; TNC: trigeminal nucleus caudalis; CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating peptide; PAC1: ■; VPAC1: ■; VPAC2: ■.
the first three days, reaching top on Day 3 (**P < 0.01), then went down on Day 7 (Figure 6 (f)). In the TG, VPAC2 on Day 1 was significantly higher than the Sham group and remained at this steady level till Day 7 (Figure 6(i): *P < 0.05, **P < 0.01). The expression pattern of VPAC2 in the TNC was surprisingly similar with that of VPAC1: reached top on Day 3 (Figure 6(j): **P < 0.01) and went down on Day 7.

**PACAP was colocalized with NeuN, PAC1 receptor, and CGRP in both TG and TNC**

Based on the similar expression patterns of PACAP, CGRP, and PAC1 in both TG and TNC, we further asked: (1) whether they are colocalized with each other? (2) Is PACAP mainly expressed in neurons? Hence, we conducted IF to study the colocalizing relationships in the TG and the TNC. NeuN is widely used
as the marker of mature neurons throughout the central nervous system. As shown in Figures 7(a) and 8(a), PACAP and NeuN were colocalized in the TG and the coexpression cells increased steadily with the repetitive stimuli: numbers on Days 3 and 7 were significantly higher than that of the Sham group (**P < 0.01). The colocalization of PACAP and CGRP was even more interesting (Figures 7(a) and 8(c)). There were much more PACAP positive cells than CGRP positive cells in the TG; and intriguingly, the majority of CGRP positive cells also expressed PACAP. This pattern was consistent with Edvinsson group’s findings in rat TG,38 and we also observed CGRP positive fibers lacking PACAP. The number of coexpressing cells rose steadily as the stimuli increased, with numbers on Day 3 and Day 7 significantly higher than the Sham group (**P < 0.01). Colocalization study in the TNC also showed that most cells that expressed NeuN, PAC1, or CGRP highly expressed PACAP (Figure 7(b)).

Figure 8. Coexpression levels of PACAP + NeuN, PACAP + PAC1, and PACAP + CGRP in the TG increased during repetitive ES. Data are represented by mean ± standard deviation, n = 6 for each group. Compared with the Sham group: ***P < 0.001; **P < 0.01.

TG: trigeminal ganglion; TNC: trigeminal nucleus caudalis; CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating peptide; PAC1: -; NeuN: —.

Discussion

The novel repetitive ES model exhibits characteristics of the chronification of acute migraine

To investigate the relation between CGRP and PACAP as well as the role of PACAP in migraine, we first established a novel repetitive ES model by stimulating the dura mater in conscious rats and evaluated this model from perspectives of cutaneous allodynia and nociceptive behaviors.

Cutaneous allodynia (CA), characterized by pain provoked by nonnoxious stimuli of the normal skin, is commonly found in migraine patients.46,47 CA is also known as a hallmark of central sensitization and an independent predictor of migraine chronification in migraine patients.48 Chemical simulation or ES of the dura mater are the two major methods for intracranial stimulation models in studying migraine.49 Several studies, including ours, have demonstrated that repetitive chemical stimulations caused a gradual worsening and spreading of CA.22,50,51 Although ES is not particular translational to clinical migraine, it does directly activate the trigeminovascular system, which is involved in the pathogenesis of migraine. We propose that repetitive ES of the dura mater will facilitate migraine chronification in a time-dependent manner, which can be indicated by the development of CA. The chronic observation showed that repetitive ES successfully elicited facial CA, with the order of sensitivity being vibrissal pad > inner canthus > outer canthus (**P < 0.001). This temporal pattern may be resulted from different sensitivities of the tested regions, as the vibrissal pad has dense mechanoreceptors that transduce deformations and convey the input to primary sensory neurons in the TG.52 Although the stimulated dura mater was innervated by the ophthalmic (V1) branch of the trigeminal nerve, the range of CA at least had spread to the maxillary (V2) branch. The acute observation, however, did not yield apparent influences, indicating that the
development of CA is not likely a transient process. There indeed were reductions in MTs upon ES from Day 1 to Day 4, whereas MTs became close to the baseline after 90 min. The variations in the time course of developing stable sensitization within groups may render the reductions inconsistent between 90 min and 24 h, while more apparent after 24 h. Collectively, our results propose that repetitive ES can elicit the CA through chronic effects.

Based on preliminary observations and previous studies, we analyzed four putative nociceptive behaviors: facial grooming, body grooming, head-flicks, and head-turning. Consistent with previous findings in our single stimulation study, facial grooming and head-flicks were more apparent in the ES group. Importantly, head-turning was only observed in the ES group. Therefore, it is reasonable to assume that head-flicks is a less serious pain-related behavior, whereas head-turning is a more severe and persistent pain-related behavior in the repetitive ES model. Taken together, our results suggest that this novel repetitive ES model exhibits some characteristics of the chronification of acute migraine.

**CGRP and PACAP are increased during repetitive ES**

CGRP has been widely acknowledged as an important neuropeptide in the pathophysiology of migraine. In this study, we found that CGRP was significantly increased in both TG and TNC correlatively with the repeats of stimuli, which provides a reasonable cause for the elevated CGRP in the saliva and circulation of migraine patients. On one hand, over release of CGRP from terminals may trigger the over expression of CGRP in the TG and the TNC to maintain the reserve pool. On the other hand, we found that CGRP was gradually elevated as stimuli increased, which is consistent with previous findings that peripheral CGRP levels were increased during intervals of migraine attacks. Therefore, this novel repetitive ES model exhibits characteristics of the frequent onset of migraine from the perspective of CGRP involvement.

PACAP showed very similar patterns with CGRP in both TG and TNC; and surprisingly, it began to increase on Day 1, suggesting that the expression of PACAP started to increase at the beginning of migraine. Trigeminal nerves innervating the dura mater release CGRP and PACAP upon activation. Our results suggest that the over release of PACAP from the TG could trigger the over expression of PACAP, which provides a reasonable explanation for the further elevation of PACAP in the plasma during migraine attacks.

**PACAP might be a novel therapeutic target for migraine: Insights from the relationship with CGRP**

Based on the IHC findings, we conducted IF staining. First, we found that PACAP was mainly expressed in neurons of both TG and TNC. Results in the TG suggested that increasing numbers of neurons were involved in migraine-like headache in conscious rats by producing PACAP.

As the highlight of this study, we demonstrated that CGRP and PACAP were colocalized in both TG and TNC, which is consistent with previous findings in the TG, and that the coexpression level in the TG increased as stimuli repeated. Interestingly, most CGRP was colocalized with PACAP, while only a part of PACAP was colocalized with CGRP. We assume that both types of PACAP+ cells may have important roles: (1) the PACAP+/CGRP- cells might be the majority that participate in migraine. They enhance the expression of PACAP upon stimulation and then increase synthesis as the stimuli repeat. (2) In addition to the first role, PACAP in the PACAP+/CGRP+ cells, the minority, may also facilitate the release of CGRP upon migraine attacks. Jansen-Olesen et al. found that exogenous administration of PACAP could induce the release of CGRP from isolated TG and TNC in a dose-dependent manner. Hence, it is reasonable to assume that the coexpressed PACAP may promote the release of CGRP from the same cell in a dose-dependent manner during repetitive stimuli.

Collectively, we propose that PACAP may be an important neuropeptide, like CGRP, in the pathophysiology of migraine. Three facts support this assumption: (1) PACAP has a similar expression pattern and a higher expression level compared with CGRP, (2) PACAP shows a more obvious increasing trend during repetitive stimuli, and (3) CGRP is mostly expressed in PACAP+ cells, which only account for a small part of all PACAP+ cells. In the light of recent findings that antibodies of CGRP and CGRP antagonists are effective in migraine prevention and acute treatment, our results highlight PACAP as a potential therapeutic target of migraine. As female sex hormones have been shown to regulate various mechanisms in migraine including CGRP and 5-hydroxytryptamine, it would be interesting to investigate whether PACAP is also influenced by sex hormones in further studies.

**PACAP is involved in migraine potentially through PAC1 receptor**

We propose that PACAP is involved in migraine potentially through PAC1 receptor. From the perspective of expression pattern, PAC1 receptor was more parallel to PACAP, whereas VPAC1 and VPAC2 were similar with...
each other. From the perspective of positive-cell numbers, PAC1 was much higher than VPAC1/2 in the TNC, showing a closer level to that of PACAP. Chaudhary and Baumann previously reported a very low mRNA level of VPAC1 in the TG compared with VPAC2 and PAC1. Indeed, mRNA levels and protein levels are not always consistent due to various transcriptional and translational regulations. Our recent study also found a lower mRNA level of VPAC1 despite comparable protein levels of three receptors in the TG. Hence, PAC1 might be the specific receptor of PACAP in migraine pathophysiology. At the beginning of the stimulation, all three receptors are increased due to the structural similarity. However, as the stimuli repeat, only the specific receptor PAC1 continues building up to catch up with the increasing PACAP. Furthermore, the TNC might be one of the specific areas in the trigeminovascular system where PACAP participates in migraine through PAC1 receptor.

Based on the IHC findings, we selectively conducted IF staining. We found that most PAC1 receptors were colocalized with PACAP in the TG and the TNC. Consistent with the IHC findings, the coexpression cells increased as the stimuli repeated. We propose that upon stimulation, neurons begin to synthesize PACAP and PAC1 receptors at the same time, and then PACAP binds to PAC1 receptor to induce downstream effects. PAC1 can act as an autoreceptor or a heteroreceptor, regulating the presynaptic release of PACAP as well as modulating the postsynaptic events through GPCR-related downstream effects. Our previous study revealed a decrease in PACAP level and a selective increase in PAC1 level in a chronic migraine model (21 days), which is supportive to this “autoreceptor hypothesis” that the further release of PACAP is regulated by a negative feedback. However, colocalization does not necessarily represent direct binding; therefore, further studies are warranted to find direct evidence elucidating the relationship between PACAP and PAC1 receptor involved in migraine.

Here, we propose a dynamic model that upon stimuli of the dura mater, the TG begins to increase the synthesis of PACAP. Some PACAP is released from periphery terminals of the TG to innervating areas such as the dura mater, resulting in vasodilation. Other PACAP is transported through central terminals to the TNC, where PACAP binds to PAC1 receptor and triggers the excitation of nociceptive neurons as well as the further increase in PACAP.

Conclusion
The novel repetitive ES model established by stimulating the dura mater in conscious rats can simulate the chronification of frequent onset of acute migraine, from the perspectives of cutaneous allodynia and nociceptive behaviors. PACAP plays a role in the pathogenesis of migraine potentially via PAC1 receptor. PACAP is coexpressed with CGRP and has the potential to be a novel therapeutic target for migraine.

Acknowledgments
The authors are grateful to professor Ruisheng Li from the 302 Hospital of the PLA General Hospital and professors Yongming Yao, Qinghong Zhang, and Jiwei Hao from the 304 Hospital of the PLA General Hospital to support our work.

Author Contributions
The final manuscript was read and approved by all authors. Qing Zhang performed the experiments, analyzed the data, generated the figures, and drafted the manuscript. Xun Han performed the preexperiments, analyzed the data, generated the figures, and drafted the manuscript. Hangfei Wu performed the preexperiments, analyzed the data, and generated the figures. Mingjie Zhang and Guanqun Hu analyzed the data and generated the figures. Shengyuan Yu and Zhao Dong designed and monitored this study and edited the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (grants 81471147, 81671077, 81471146, 81500966, 81500943, and 81600952), Beijing Science and Technology Project (grant Z161100002616013), the Capital Development Scientific Research (grant 2014-4-5013), and Beijing Natural Science Foundation (grant 7162178).

References
1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–1602.
2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML and Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–349.
3. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M and Steiner T. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 2012; 52: 582–591.
4. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C and Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017; 97: 553–622.

5. Uddman R, Goadsby PJ, Jansen I and Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon carotid arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993; 13: 291–297.

6. Petersen KA, Birk S, Doods H, Edvinsson L and Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004; 143: 697–704.

7. Vollesen ALH, Amin FM and Ashina M. Targeted pituitary adenylate cyclase-activating peptide therapies for migraine. Neurotherapeutics 2018; 15: 371–376.

8. Jansen-Olesen I and Hougaard Pedersen S. PACAP and its receptors in cranial arteries and mast cells. J Headache Pain 2018; 19: 16.

9. Strother LC, Srikiatkhachorn A and Supronsinchai W. Targeted orexin and hypothalamic neuropeptides for migraine. Neurotherapeutics 2018; 15: 377–390.

10. Zagami AS, Edvinsson L and Goadsby PJ. Pituitary adenylate cyclase-activating polypeptide and migraine. Ann Clin Transl Neurol 2014; 1: 1036–1040.

11. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J and Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16–25.

12. Vollesen AL, Guo S and Ashina M. PACAP38 dose-response pilot study in migraine patients. Cephalalgia 2017; 37: 391–395.

13. Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, Toth E, Kinces ZT, Vecsei L and Tajti J. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013; 33: 1085–1095.

14. Han X, Dong Z, Hou L, Wan D, Chen M, Tang W and Yu S. Intercellular plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache. Clin Chim Acta 2015; 450: 151–154.

15. Amin FM, Ashgar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJ, Larsson HB, Olesen J and Ashina M. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012; 32: 140–149.

16. Markovics A, Kormos V, Gaszner B, Lashgarara A, Szoke E, Sandor K, Szabadi K, Tuka B, Tajti J, Szolcsanyi J, Pinter E, Hashimoto H, Kun J, Reglodi D and Helyes Z. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis 2012; 45: 633–644.

17. Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christiansen DV and Olesen J. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 2014; 48: 53–64.

18. Harma AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA and Said SI. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012; 166: 4–17.

19. Amin FM, Hougaard A, Schytz HW, Ashgar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J and Ashina M. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 2014; 137: 779–794.

20. Akerman S and Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigemino-cerebral neurons: relevance to migraine. Sci Transl Med 2015; 7: 308ra157.

21. Chan KY, Baun M, de Vries R, van den Bogaert JD, Dirven CMF, Danser AHJ, Jansen-Olesen I, Olesen J, Villálon CM, MaassenVanDenBrink A and Gupta S. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 2011; 31: 181–189.

22. Han X, Ran Y, Su M, Liu Y, Tang W, Dong Z and Yu S. Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats. Mol Pain 2017; 13: 1744806917720361.

23. Goadsby PJ, Edvinsson L and Ekram R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–187.

24. Goadsby PJ and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48–56.

25. Ho TW, Edvinsson L and Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6: 573–582.

26. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H and Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115–2123.

27. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J and Lenz MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115–2123.

28. Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Chan KY, Baun M, van der Geest RJ, de Koning PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J and Lenz MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115–2123.

29. Kaiser EA and Russo AF. CGRP and migraine: could they be the same? Cephalalgia 2012; 47: 451–461.

30. Bigal ME and Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009; 27: 321–334.

31. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
32. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 1983; 16: 109–110.

33. Dong Z, Jiang L, Wang X, Wang X and Yu S. Nociceptive behaviors were induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus in conscious adult rats and reduced by morphine and rizatriptan benzoate. *Brain Res* 2011; 1368: 151–158.

34. Jiang L, Dong Z, Li F, Liu R, Qiu E, Wang X and Yu S. Microarray analysis of gene expression after electrical stimulation of the dura mater surrounding the superior sagittal sinus in conscious adult rats. *Clin Med J* 2014; 127: 734–741.

35. Chaplan SR, Bach FW, Pogrel JW, Chung JM and Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. *J Neurosci Methods* 1994; 53: 55–63.

36. Malatesta M. Histological and histochemical methods – theory and practice. *Eur J Histochem* 2010; 60: 2639.

37. Castorina A, Scuderi S, D’Amico AG, Drago F and D’Agata V. PACAP and VIP increase the expression of myelin-related proteins in rat schwannoma cells: involvement of PAC1/VPAC2 receptor-mediated activation of PI3K/Akt signaling pathways. *Exp Cell Res* 2014; 322: 108–121.

38. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z and Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. *Brain Res* 2015; 1600: 93–109.

39. Kanasaki H, Mijiddorj T, Sukhbaatar U, Oride A and Miyazaki K. Pituitary adenylate cyclase-activating polypeptide (PACAP) increases expression of the gonadotropin-releasing hormone (GnRH) receptor in GnRH-producing GT1-7 cells overexpressing PACAP type I receptor. *Gen Comp Endocrinol* 2013; 193: 95–102.

40. Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L and Warfvinge K. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. *Neuroscience* 2012; 202: 158–168.

41. Cortesi T, Tuka B, Tajti J, Bagoly T, Fulop F, Helyes Z and Vecsei L. Kynurenic acid inhibits the electrical stimulation induced elevated pituitary adenylate cyclase-activating polypeptide expression in the TNC. *Front Neurol* 2017; 8: 745.

42. Borsani E, Albertini R, Labanca M, Lonati C, Rezzani R and Rodella LF. Peripheral purinergic receptor modulation influences the trigeminal ganglia nitrosergic system in an experimental murine model of inflammatory orofacial pain. *J Neurosci Res* 2010; 88: 2715–2726.

43. Zhang M, Dai W, Liang J, Chen X, Hu Y, Chu B, Pan M, Dong Z and Yu S. Effects of UCMS-induced depression on nociceptive behaviors induced by electrical stimulation of the dura mater. *Neurosci Lett* 2013; 551: 1–6.

44. Noseda R, Constandil L, Bourgeais L, Chalus M and Villanueva L. Changes of meningeal excitability mediated by corticotrigeminal networks: a link for the endogenous modulation of migraine pain. *J Neurosci* 2010; 30: 14420–14429.

45. Paxinos G, Watson C. *The rat brain in stereotaxic coordinates*. 6 ed. UK: Elsevier Inc., 2007, p.348.

46. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ and Bajwa ZH. An association between migraine and cutaneous allodynia. *Ann Neurol* 2000; 47: 614–624.

47. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D and Stewart WF. Cutaneous allodynia in the migraine population. *Ann Neurol* 2008; 63: 148–158.

48. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD and Terwindt GM. Cutaneous allodynia as a predictor of migraine chronification. *Brain* 2013; 136: 3489–3496.

49. Storer RJ, Supronsinchhai W and Srikiatkhachorn A. Animal models of chronic migraine. *Curr Pain Headache Rep* 2015; 19: 467.

50. Boyer N, Dallel R, Artola A and Monconduit L. General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression. *Pain* 2014; 155: 1196–1205.

51. Hu G, Zhang M, Su M, Zhang Q, Wu H, Wang X, Dong Z and Yu S. Wider range of allodynia in a rat model of repeated dural nociception compared with infraorbital nerve chronic constriction injury. *Neurosci Lett* 2018; 660: 120–126.

52. Ebara S, Kumamoto K, Matsuura T, Mazurkiewicz JE and Rice FL. Similarities and differences in the innervation of mystacial vibrissal follicle-sinus complexes in the rat and cat: a confocal microscopic study. *J Comp Neurol* 2002; 449: 103–119.

53. Bellamy JL, Cady RK and Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. *Headache* 2006; 46: 24–33.

54. Cady RK, Vause CV, Ho TW, Bigal ME and Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. *Headache* 2009; 49: 1258–1266.

55. Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Reed ML, Serrano D and Stewart WF. Cutaneous allodynia in the migraine population. *Ann Neurol* 2008; 63: 148–158.

56. Chaudhary P and Baumann TK. Expression of VPAC2 receptor and PAC1 receptor splice variants in the trigeminal ganglion of the adult rat. *Brain Res Mol Brain Res* 2002; 104: 137–142.